Skip to main content
. 2019 Apr 20;12(4):343–349. doi: 10.1111/cts.12636

Figure 2.

Figure 2

(a) External validation for the final quantitative systems pharmacology (QSP) model using the mean maximal concentration of chimeric antigen receptor T‐cell (CART) peak plasma concentration (Cmax) and the mean area under the curve of the time‐concentration curve from t = 0 to t = 28 days (AUC 0–28) of the typical kinetics of CART in chronic lymphatic leukemia (CLL). Symbols and bars represent the predicted and observed log‐transformed mean and SD values. (b) Simulated CART and cytokine kinetic profiles with different B‐cell disease burden and anti‐CD19 CART doses in a patient with CLL, CART baseline in peripheral blood (PB): 1.1 × 109 cells (UPN1) and 1.4 × 107 cells (UPN3), disease burden baseline in PB: 4.14 × 109 cells (UPN1) and 9.3 × 108 cells (UPN3). IFNγ, gamma interferon; IL, interleukin.